25 May 2021 - The Annual General Meeting of EXACT Therapeutics AS ('EXACT-Tx' or
the 'Company') will be held on 1 June 2021 at 1300hrs CET. Please find attached
the notice of Annual General Meeting with attendance/Proxy, including the Board
of Directors' proposed resolutions for the items listed on the agenda. The
documents are also available at www.exact-tx.com
 
Due to the COVID-19 situation the Company's office is closed and the Annual
General Meeting will be held by proxy or by submitting votes in advance.
Shareholders who notify the company will be invited to participate in a
Microsoft Teams meeting, but votes need to be cast in advance. The deadline for
receiving proxies or votes is 30 May 2021 at 12:00 CET. The Annual General
Meeting will be efficiently carried through by strictly keeping to the agenda
items. 
 
For further information, please contact: Masha Stromme, Chair of the Board +47
930 22 509, masha_stromme@fastmail.fm
 
About EXACT Therapeutics AS: EXACT-Tx is a clinical stage Norwegian biotech
company developing a technology platform for targeted therapeutic enhancement -
Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to
ultrasound-mediated, targeted drug enhancement - with the potential to
significantly amplify the clinical utility of a wide range of therapeutic agents
across a multitude of indications including within oncology (chemotherapy,
immunotherapy), infectious diseases, and neurological conditions.
www.exact-tx.com